EP0518961A1 - Glycinamidderivate, ihre herstellung und diese enthaltende arzneimittel - Google Patents

Glycinamidderivate, ihre herstellung und diese enthaltende arzneimittel

Info

Publication number
EP0518961A1
EP0518961A1 EP91905834A EP91905834A EP0518961A1 EP 0518961 A1 EP0518961 A1 EP 0518961A1 EP 91905834 A EP91905834 A EP 91905834A EP 91905834 A EP91905834 A EP 91905834A EP 0518961 A1 EP0518961 A1 EP 0518961A1
Authority
EP
European Patent Office
Prior art keywords
alk
alkyl
quinolyl
phenyl
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91905834A
Other languages
English (en)
French (fr)
Inventor
Jean-Dominique Bourzat
Marc Capet
Claude Cotrel
Claude Guyon
Franco Manfre
Gérard Roussel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Aesculap JBS SA
Original Assignee
Rhone Poulenc Rorer SA
JBS SA France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9002890A external-priority patent/FR2659324B1/fr
Priority claimed from FR9003838A external-priority patent/FR2659966B1/fr
Priority claimed from FR9011651A external-priority patent/FR2667066B2/fr
Application filed by Rhone Poulenc Rorer SA, JBS SA France filed Critical Rhone Poulenc Rorer SA
Publication of EP0518961A1 publication Critical patent/EP0518961A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP91905834A 1990-03-07 1991-03-05 Glycinamidderivate, ihre herstellung und diese enthaltende arzneimittel Withdrawn EP0518961A1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR9002890 1990-03-07
FR9002890A FR2659324B1 (fr) 1990-03-07 1990-03-07 N-heterocyclyl glycinamides, leur preparation et les medicaments les contenant.
FR9003838 1990-03-26
FR9003838A FR2659966B1 (fr) 1990-03-26 1990-03-26 Derives de n-aralkyl glycinamide, leur preparation et les medicaments les contenant.
FR9011651A FR2667066B2 (fr) 1990-03-07 1990-09-21 N-heterocyclyl glycinamides, leur preparation et les medicaments les contenant.
FR9011651 1990-09-21

Publications (1)

Publication Number Publication Date
EP0518961A1 true EP0518961A1 (de) 1992-12-23

Family

ID=27252167

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91905834A Withdrawn EP0518961A1 (de) 1990-03-07 1991-03-05 Glycinamidderivate, ihre herstellung und diese enthaltende arzneimittel

Country Status (10)

Country Link
EP (1) EP0518961A1 (de)
JP (1) JPH05504968A (de)
AU (1) AU650261B2 (de)
CA (1) CA2074357A1 (de)
HU (1) HU210581B (de)
IE (1) IE910745A1 (de)
IL (1) IL97475A0 (de)
NZ (1) NZ237339A (de)
PT (1) PT96970A (de)
WO (1) WO1991013874A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658518B1 (fr) * 1990-02-19 1992-04-30 Rhone Poulenc Sante N-phenyl n-alcoxycarbonylalkyle glycinamides, leur preparation et les medicaments les contenant.
FR2695641B1 (fr) * 1992-09-11 1994-11-25 Rhone Poulenc Rorer Sa (Amino-3 phényl)-1 éthanesulfonate d'hydroquinine optiquement actif, sa préparation et son utilisation.
EP0746544B1 (de) * 1994-02-22 1998-09-09 Merrell Pharmaceuticals Inc. Indolderivate zur behandlung von östrogenabhängigen neoplasmen und krankheiten
FR2723739B1 (fr) * 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
US6107329A (en) * 1995-06-06 2000-08-22 Pfizer, Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
US6297269B1 (en) 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
KR100241643B1 (ko) 1995-06-06 2000-03-02 디. 제이. 우드 당뇨병치료제인 치환된 N-(인돌-2-카르보닐)-β-알라님아미드 및 그의 유도체
US6696475B2 (en) 1997-04-22 2004-02-24 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
AP2001002103A0 (en) 1998-10-22 2001-03-31 Neurosearch As Substituted phenyl derivatives, their preparation and use.
US6277877B1 (en) 2000-08-15 2001-08-21 Pfizer, Inc. Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
DE60325834D1 (de) * 2002-02-20 2009-03-05 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
US6933311B2 (en) 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
MX2009002018A (es) 2006-08-25 2009-03-05 Abbott Lab Derivados de indazol que inhiben vanilloide-1 potencial de receptor pasajero (trpv1) y usos de los mismos.
CN101563318A (zh) 2006-12-20 2009-10-21 艾博特公司 作为trpv1香草素受体拮抗剂用于治疗疼痛的n-(5,6,7,8-四氢萘-1-基)脲衍生物以及相关化合物
EP2323989A4 (de) 2008-03-20 2011-06-22 Abbott Lab Verfahren zur herstellung von auf das zentrale nervensystem wirkenden mitteln, bei denen es sich um trpv1-antagonisten handelt
CN114181133B (zh) * 2021-11-24 2023-04-28 上海应用技术大学 一种甘氨酸衍生乙酰胺化合物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0166355A2 (de) * 1984-06-26 1986-01-02 Merck & Co. Inc. Substituierte Aminophenyl- und Acylaminophenyl-Verbindungen und deren pharmazeutische Zusammensetzungen
US4814463A (en) * 1985-12-31 1989-03-21 Biomeasure, Inc. CCK antagonists
FR2624698A1 (fr) * 1987-12-18 1989-06-23 Bernard Lyon I Universite Clau Derives heterocycliques de n-carbamoyl-, n-thiocarbamoyl- ou n-amidino-aminomalonyl ou aminosuccinyl amides utiles comme agents edulcorants
EP0442878A4 (en) * 1988-04-05 1991-10-23 Abbott Laboratories Derivatives of tryptophan as cck antagonists
CA1326108C (en) * 1988-04-12 1994-01-11 Sun Hyuk Kim Cck antagonists
FR2658518B1 (fr) * 1990-02-19 1992-04-30 Rhone Poulenc Sante N-phenyl n-alcoxycarbonylalkyle glycinamides, leur preparation et les medicaments les contenant.
FR2667864B2 (fr) * 1990-03-07 1994-08-05 Rhone Poulenc Sante Derives de n-phenyl glycinamides, leur preparation et les medicaments les contenant.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9113874A1 *

Also Published As

Publication number Publication date
IE910745A1 (en) 1991-09-11
IL97475A0 (en) 1992-06-21
WO1991013874A1 (fr) 1991-09-19
JPH05504968A (ja) 1993-07-29
HU9202864D0 (en) 1992-11-30
AU650261B2 (en) 1994-06-16
AU7454191A (en) 1991-10-10
NZ237339A (en) 1992-10-28
HU210581B (en) 1995-05-29
PT96970A (pt) 1991-10-31
CA2074357A1 (fr) 1991-09-08
HUT61731A (en) 1993-03-01

Similar Documents

Publication Publication Date Title
EP0679161B1 (de) Thiazolidinederivate ihre herstellung und sie enthaltende medikamente
WO1991013874A1 (fr) Derives de glycinamide, leur preparation et les medicaments les contenant
FR2678938A1 (fr) Derives de pyrrolidine, leur preparation et les medicaments les contenant.
EP0766696B1 (de) Thiazolidinderivate, ihre herstellung und medikamente, die sie enthalten
EP0607355B1 (de) 3-ureido-benzodiazepinone verwendbar als cck- oder gastrin-antagonisten
EP0678098A1 (de) Pyrollidin- und thiazolidinderivate, ihre herstellung und sie enthaltende medikamente
EP0518960B1 (de) N-phenylglycinderivate, ihre herstellung und medikamente, die sie enthalten
EP0514442B1 (de) N-phenyl-n-acetamidoglycinamide, ihre herstellung und medikamente, die sie enthalten
EP0520016B1 (de) Harnstoffderivate, ihre herstellung und deren enthaltende arzneimittel
EP0397556A1 (de) N-Phenylamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
FR2700166A1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
EP0516729B1 (de) N-phenyl-n-alkoxycarbonylalkyl-glycinamide, ihre herstellung und sie enthaltende medikamente
EP0678088B1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
EP0766695B1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen
EP0662081B1 (de) Ureidoacetamid-derivate,irhe herstellung und sie enthaltende medikamente
FR2667066A2 (fr) N-heterocyclyl glycinamides, leur preparation et les medicaments les contenant.
FR2659966A1 (fr) Derives de n-aralkyl glycinamide, leur preparation et les medicaments les contenant.
FR2659324A1 (fr) N-heterocyclyl glycinamides, leur preparation et les medicaments les contenant.
FR2659334A1 (fr) Derives de n-phenyl glycinamide, leur preparation et les medicaments les contenant.
FR2667319A2 (fr) N-phenyl n-acetamido glycinamides, leur preparation et les medicaments les contenant.
FR2667863A2 (fr) N-phenyl n-acetamido glycinamides, leur preparation et les medicaments les contenant.
FR2658196A1 (fr) N-phenyl n-acetamido glycinamides leur preparation et les medicaments les contenant.
WO1994006824A1 (fr) Derive d'ureido-acetamide optiquement actif, sa preparation et les medicaments les contenant

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920818

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19931210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950613